Calculate your SIP ReturnsExplore

Gufic Biosciences Receives Approval for Acute Pain Treatment: Stock Surges

12 September 20233 mins read by Angel One
Gufic Biosciences has received approval from the Therapeutic Group Administration in Australia and the National Health Surveillance Agency in Brazil for Parecoxib Sodium 40mg Lyophilized Powder for Injection.
Gufic Biosciences Receives Approval for Acute Pain Treatment: Stock Surges
ShareShare on 1Share on 2Share on 3Share on 4Share on 5

Gufic Biosciences Limited (Gufic) has received approval from the Therapeutic Group Administration (TGA) in Australia and the National Health Surveillance Agency (ANVISA) in Brazil for Parecoxib Sodium 40mg Lyophilized Powder for Injection, a selective COX-2 inhibitor that will be used in adult patients for the short-term treatment of acute pain and post-operative pain. Gufic has remained devoted to saving and enhancing the lives of people throughout the world through its ongoing efforts through international regulatory authorities to deliver innovative compounds to the world. 

Parecoxib Sodium is the first parenteral selective COX-2 inhibitor approved for therapeutic use in the treatment of pain. To minimise the gastrointestinal adverse effects associated with COX-1 inhibitors, selective COX-2 inhibitors were created. Parecoxib is a prodrug of Valdecoxib, a powerful anti-inflammatory and analgesic sulphonamide-based COX-2 inhibitor. Parecoxib is rapidly converted to Valdecoxib in the liver after a single intravenous (IV) or intramuscular (IM) injection. 

The first apparent analgesic impact of parecoxib occurs within seven to thirteen minutes, with a peak effect occurring within two hours of delivery of a single dosage of 40mg injection through IV or IM route. When coupled with morphine, parecoxib has more significant synergistic effects than other COX-2 NSAIDs and decreases the quantity of opioid required for effective analgesia. This total opioid medication decrease increases the analgesic regime’s safety margin and provides improved analgesic coverage. 

Shares of Gufic Biosciences are currently trading at Rs 302.70, up by 6.25 points or 2.11% from its previous closing of Rs 296.45 on the BSE. The scrip opened at Rs 307 and has touched a high and low of Rs 318.30 and Rs 291.25, respectively. So far 33306 shares have been traded on the counter.  

The BSE group ‘B’ stock of face value Rs 1 has touched a 52-week high of Rs 339.55 and a 52-week low of Rs 177.10. Last one week high and low of the scrip stood at Rs 318.30 and Rs 291.25, respectively. The current market cap of the company is Rs 2901.06 crore.  

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.

 

Enjoy Zero Brokerage on Equity Delivery
4.4 Cr+DOWNLOADS
Enjoy Zero Brokerage on Equity Delivery

Get the link to download the App

Send App Link

Enjoy Zero Brokerage on
Equity Delivery